New ultrasound technique detects fetal circulation problems
Researchers have developed a new ultrasound technique to monitor the placent...Read more on AuntMinnie.comRelated Reading:
X-ray, CT reveal mummified ancient Egyptian was pregnant
Fetal cardiovascular MRI helps diagnose congenital heart defects
Lung ultrasound spots COVID-19 in newborns
Pregnancy is safe for breast cancer survivors
Imaging detects big, rare tumor protruding from fetus's mouth (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 11, 2021 Category: Radiology Source Type: news
Reinventing the Uterus, One Organoid at a Time
Bioengineer Linda Griffith once grew a human ear on the back of a mouse. Now she is reframing endometriosis — a “women’s disease” — as a key to unlocking some of biology’s greatest secrets. (Source: NYT Health)
Source: NYT Health - April 27, 2021 Category: Consumer Health News Authors: Rachel E. Gross Tags: your-feed-science your-feed-health Endometriosis Menstruation Reproduction (Biological) Tissue (Human) Pregnancy and Childbirth Gynecology and Gynecologists Breast Cancer Biotechnology and Bioengineering Hysterectomies Source Type: news
Studies connect hormone to breast cancer and uncover potential for novel targeted drugs
(Virginia Commonwealth University) The hormone prolactin has long been understood to play a vital role in breast growth and development and the production of milk during pregnancy. But a pair of recent studies conducted at VCU Massey Cancer Center finds strong evidence that prolactin also acts as a major contributor to breast cancer development and that the hormone could inform the creation of targeted drugs to treat multiple forms of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news
Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Inflammation a key to targeting pregnancy-associated breast cancer
(Garvan Institute of Medical Research) Targeting the tumour environment may help improve treatments for breast cancers affecting pregnant women and young mothers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2021 Category: Cancer & Oncology Source Type: news
Propylparaben exposure during pregnancy may reduce protection against breast cancer
(The Endocrine Society) Low doses of propylparaben--an estrogen-like chemical used as a preservative in personal care products and foods--can alter pregnancy-related changes in the breast in ways that may reduce the normal protection against breast cancer that pregnancy hormones convey, according to a new study being published in the Endocrine Society's journalEndocrinology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2021 Category: Cancer & Oncology Source Type: news
Exposure to common chemical during pregnancy may reduce protection against breast cancer
(University of Massachusetts Amherst) Low doses of propylparaben - a chemical preservative found in food, drugs and cosmetics - can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer that pregnancy hormones normally convey, according to University of Massachusetts Amherst research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2021 Category: Cancer & Oncology Source Type: news
Cochrane community participates in a virtual walk to raise money for Anne Anderson Award
The global Cochrane community are walking andraising money for the annual Anne Anderson Award, which is given to a Cochrane member who has contributed meaningfully to the promotion of women as leaders and contributors to the organization.Given we can ' t meet in-person for our 2021 Anne Anderson Walk, we are doing it virtually. Participants are making donations and sharing pictures themselves on their walk or their local area - click on the map below to see! Who is Anne Anderson?Anne Anderson was a contributor to the stream of thinking and effort that gave birth to evidence-based health care. A clinically qualified repro...
Source: Cochrane News and Events - February 25, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
International Women's Day Panel on diversity in health evidence synthesis - 8 March 2021
International Women ' s Day is March 8th! Join us as we discuss and highlight minority women and young investigators working in health science and evidence synthesis. Hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis. Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis. In the past it ' s been the ' Ann Anderson Walk ' at the Cochrane Colloquium to raise money for theannual A...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
International Women's Day Panel on diversity in health evidence synthesis
On International Women ' s Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis. Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis. Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis. In the past it ' s been the ' Anne Anderson Walk ' at the Cochrane Colloquium to raise money for ...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
VIDEO: International Women's Day Panel on diversity in health evidence synthesis
On International Women ' s Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis. Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis. Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis. In the past it ' s been the ' Anne Anderson Walk ' at the Cochrane Colloquium to raise money for ...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Pregnancy After Breast Cancer Doesn't Increase Recurrence Risk Pregnancy After Breast Cancer Doesn't Increase Recurrence Risk
Among women who became pregnant, breast cancer survivors did not have higher odds of miscarriage or complications like preeclampsia, and their babies were not more likely to have congenital abnormalities.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
